Description
| Author/Contributor(s): | Sharp, Kathleen |
| Publisher: | Plume |
| Date: | 8/28/2012 |
| Binding: | Paperback |
| Condition: | NEW |
“Blood Feud rivals A Civil Action for best non-fiction bookof the past twenty years.” — John Lescroart, New York Times bestselling author ofDamage
Procrit seemed like a biotech miracle, promising a golden age in medicalcare. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant,Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billionsin annual revenue—and still does. In2012, world famous cyclist, Olympian, and Tour de France champion LanceArmstrong was banned from professional cycling on doping charges for using EPO(the blanket name for the drugs Procrit and Epogen), resulting in a globalcontroversy about abuse, big pharmaceutical companies, and the lies andinaccuracies concerning performance-enhancing drugs.
MarkDuxbury was a J&J salesman who once believed in the blood-booster, settingrecord sales and winning company awards. Then Duxbury started to learn unsavorytruths about Procrit and J&J’s business practices. He was fired and filed awhistleblower suit to warn the public.
When Jan Schlichtman (A Civil Action) learned of Duxbury’scrusade, he signed on. Now, he’s fighting on behalf of cancer patients and forevery American who trusts Big Pharma with his life.
Reviews
There are no reviews yet.